Nitrogen In Aglycone Moiety Patents (Class 536/17.9)
-
Patent number: 6664235Abstract: A medicament for treatment of a viral infection which comprises as an active ingredient a compound represented by the following formula (I) or its Pharmaceutically acceptable salt, or a hydrate thereof or a solvate thereof.Type: GrantFiled: August 18, 2000Date of Patent: December 16, 2003Assignee: RikenInventors: Osamu Kanie, Chi-Huey Wong, Yasuo Suzuki
-
Patent number: 6645940Abstract: An oligosaccharide derivative, at higher homogeneity than fucose polysaccharide and rhamnose polysaccharide and with greater antiulcer effects, which is represented by the following general formula: Y—OCH(CH2NHR)2 wherein, Y represents an oligofucose or oligorhamnose at a polymerization number of 2 to 20, where the hydroxyl groups may or may not be partially modified in the form of sulfate ester, and R represents phenyl group, a higher alkylphenyl group, a higher alkyl group or —(CH2)n—NHX wherein n is an integer of 1 to 10 and X represents a higher alkanoyl group or an alkylamino group.Type: GrantFiled: December 6, 2002Date of Patent: November 11, 2003Assignee: Kabushiki Kaisha Yakult HonshaInventors: Masato Nagaoka, Hideyuki Shibata, Itsuko Kimura, Shusuke Hashimoto
-
Patent number: 6635622Abstract: The present invention is a compound of general formula (I) or a pharmaceutically acceptable salt of, wherein W represents carbon chain from 9 to 17 which containing double bond or hydroxy group occasionally; X represents carbon chain from 11 to 25 which containing double bond or hydroxy group occasionally; Y represents —(CH2)a—CH═CH—(CH2)a′—, —(CH2)a— (a, a′ denotes an integer of 0-5 and a+a′ is 5 and under.), —S(O)0-2CH2—, —NHCH2—; Z represents —CO—, —SO2—; R represents —CH2OH, CO2H, CH2OCH2CO2SO3H; R0 represents —OH, —NH2, —NHAc.Type: GrantFiled: June 12, 2001Date of Patent: October 21, 2003Assignee: Kotobuki Pharmaceutical Co., Ltd.Inventors: Hiroshi Tomiyama, Takashi Yanagisawa, Masayuki Nimura, Atsushi Noda, Tsuyoshi Tomiyama
-
Patent number: 6627744Abstract: The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine n a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue with a glycosylated thiosulfonate. Also a method of producing the chemically modified mutant protein is provided. The present invention also relates to a glycosylated methanethiosulfonate. Another aspect of the present invention is a method of modifying the functional characteristics of a protein including providing a protein and reacting the protein with a glycosylated methanethiosulfonate reagent under conditions effective to produce a glycoprotein with altered functional characteristics as compared to the protein. In addition, the present invention relates to methods of determining the structure-function relationships of chemically modified mutant proteins.Type: GrantFiled: April 2, 2001Date of Patent: September 30, 2003Assignee: Genencor International, Inc.Inventors: Benjamin G. Davis, John Bryan Jones, Richard R. Bott
-
Patent number: 6620442Abstract: The invention provides a process for reducing odor, bitterness, astringency and pungency of a Simmondsins extract by dissolving the Simmondsins extract in a solvent if the Simmondsins extract is in a dry form, reacting the liquid Simmondsins extract with a carbonaceous adsorbent, such as activated carbon, to obtain a mixture, separating the adsorbent from the mixture to obtain a purified liquid extract, and drying the purified liquid extract.Type: GrantFiled: August 24, 2001Date of Patent: September 16, 2003Assignee: International Flora Technologies, Inc.Inventors: Qingnong Tang, James Howard Brown, Wenhui Fu
-
Patent number: 6610835Abstract: Derivatives of sphingolipids of the formula: are provided wherein the substituents are as defined in the specification and wherein there is at least one R2 substituent in the sphingolipid derivative. The compounds are useful in the treatment of of abnormal cell proliferation, including benign and malignant tumors, the promotion of cell differentiation, the induction of apoptosis, the inhibition of protein kinase C, and the treatment of inflammatory conditions, psoriasis, inflammatory bowel disease as well as proliferation of smooth muscle cells in the course of development of plaques in vascular tissue. The invention also includes a method for triggering the release of cytochrome c from mitochondria that includes administering an effective amount of a sphingolipid or its derivative or prodrug to a host in need thereof.Type: GrantFiled: February 12, 1999Date of Patent: August 26, 2003Assignee: Emory UniversityInventors: Dennis C. Liotta, Alfred H. Merrill, Jr., Thomas E. Keane, Kapil N. Bhalla, Eva M Schmelz
-
Publication number: 20030139349Abstract: The invention concerns (i) [4-(4-cyanobenzyl)phenyl]&agr;-D-glycopyranosides of formula (I) wherein: the group &agr;-D-glycopyranosyl R represents a &agr;-D-glycopyranosyl, &agr;-D-galactopyranosyl. &agr;-D-mannopyranosyl, &agr;-D-arabinopyranosyl, &agr;-D-lyxopyranosyl, or &agr;-D-ribopyranosyl group: (ii) their esters resulting from the esterification of at least a OH function of each pyranosyl group with a C2-C4 alkanoic or a cycloalkanoic acid, as novel industrial products. Said novel [4-(4-cyanobenzyl)phenyl]&agr;-D-glycopyranosides are useful in therapy for fighting against atheromatous plaque.Type: ApplicationFiled: September 5, 2002Publication date: July 24, 2003Inventors: Luc Lebreton, Christiane Legendre, Soth Samreth
-
Patent number: 6590085Abstract: This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection and psoriasis. This invention also relates to pharmacological compositions containing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid and the methods of treating such pathologies as listed above.Type: GrantFiled: March 25, 1999Date of Patent: July 8, 2003Assignee: Ranbaxy Laboratories LimitedInventors: Sudershan K Arora, Nawal Kishore, Jang Bahadur Gupta, Vishwas D Joshi
-
Publication number: 20030109461Abstract: The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention comprises at least one aryl, heteroaryl, substituted aryl or substituted heteroaryl group in place of a glycosyl group attached to the 2-deoxystreptamine ring.Type: ApplicationFiled: November 19, 2002Publication date: June 12, 2003Inventors: Eric Swayze, Richard H. Griffey, Yili Ding, Venkatraman Mohan
-
Publication number: 20030100515Abstract: The invention concerns: (i) [4-(4-cyanobenzyl)phenyl]glycopyranosides of formula (I) wherein; the glycopyranosyl group R represents a &bgr;-D arabinopyranosyl, &bgr;-D-lyxopyranosyl, &bgr;-D-ribopyranosyl, &bgr;-D-mannopyranosyl, &bgr;-L-arabinopyranosyl, &bgr;-L-xylopyranosyl, &agr;-L-arabinopyranosyl, &agr;-L-xylopyranosyl or &bgr;-L-rhamnopyranosyl group; and (ii) their esters resulting from esterification of at least a OH function of each glycopyranosyl group with a C2-C4 alkanoic or cycloalkanoic acid, as novel industrial products. Said novel [4-(4-cyanobenzyl)phenyl]glycopyranosides are useful in therapy for fighting against athermatous plaque.Type: ApplicationFiled: September 6, 2002Publication date: May 29, 2003Inventors: Luc Lebreton, Christiane Legendre, Soth Samreth
-
Patent number: 6562792Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X, Y, V, W1, W2, Z1 and Z2 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods of treating bacterial and protozoal infections in mammals by administering the above compounds.Type: GrantFiled: October 20, 2000Date of Patent: May 13, 2003Assignee: Pfizer Inc.Inventors: Katherine E. Brighty, Robert G. Linde, Takushi Kaneko, Matthew M. Hayward
-
Patent number: 6555519Abstract: SGLT2 inhibiting compounds are provided having the formula wherein n is 0, 1 or 2; A is or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO2, bearing substituents R3 and R4; and R1 to R4 are as defined herein. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents.Type: GrantFiled: February 23, 2001Date of Patent: April 29, 2003Assignee: Bristol-Myers Squibb CompanyInventor: William N. Washburn
-
Patent number: 6548484Abstract: Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds according to FORMULA V, wherein, Ring 1 comprises a cyclic or heterocyclic ring, or aryl or heteroaryl ring, all of said rings comprising 4 to 8 carbon atoms, among which atoms are counted “X” and “Y”; R0, R1, R2, R3 and R4 comprise substituents of Ring 1; either of X or Y is optional; each of X and Y, when present comprise a carbon atom, a halogen atom or a lower alkyl; Z, R5 and R5′ are optional; when Z is present it comprises a lower alkyl having substituents R5, R5′; R6 and R6′ comprise substituents on a carbon atom linking Z with N through a single bond, or when Z is absent, linking N with Ring 1; N comprises a nitrogen atom of an amine or an amide linked with E through a single bond and having R7 as a substituent; and E comprises a saccharide.Type: GrantFiled: April 12, 2000Date of Patent: April 15, 2003Assignee: International Medical Innovations, Inc.Inventor: Samuel T. Christian
-
Publication number: 20030060430Abstract: A method of making a derivatized aminoglycoside includes reacting an aminoglycoside with at least 2 equivalents of a divalent metal ion in an aprotic solvent to complex two neighboring amino group and hydroxyl group pairs; reacting the non-complexed amino groups with a protecting reagent to provide protecting groups; removing the divalent metal ion to provide two unprotected amino groups; reacting one of the unprotected amino groups with a reactive substance containing an linker, a carrier, or a label; and removing the protecting groups. This method can be used to produce novel compounds and reagents.Type: ApplicationFiled: July 31, 2001Publication date: March 27, 2003Inventors: Mitali Ghoshal, Salvatore J. Salamone
-
Patent number: 6534637Abstract: This invention provides &bgr;-D-Glucuronidase substrates of the formula: wherein R1, R2, and R7-R12 are independently selected from the group consisting of: hydrogen, fluorine, chlorine, bromine, iodine, alkyl, hydroxyl, alkoxy, carboxyl and nitro groups; R3-R6 are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, nitro and amino; and M+ is selected from the group consisting of: proton, lithium, sodium, potassium, magnesium, calcium, barium, and ammonium ion.Type: GrantFiled: February 12, 2001Date of Patent: March 18, 2003Assignee: Beckman Coulter, Inc.Inventors: Gene G. Y. Shen, Chan S. Oh, Stephanie D. Yancey, Craig W. Adams
-
Patent number: 6531454Abstract: Glycosylated polyamines comprising of mono- or oligo-saccharides that are glycosidically linked to an aliphatic polyamine, and pharmaceutically acceptable salts, prodrugs and derivatives thereof are provided. An exemplary glycosylated polyamine has the following structure: Glycosylated polyamines, their pharmaceutically acceptable salts, prodrugs and derivatives are useful, for example, as anticancer compounds for the treatment of a variety of cancers. Methods for synthesis of glycosylated polyamines are disclosed. In addition, metal complexes of glycosylated polyamines, the preparation of such metal complexes, analytical methods using the metal complexes are provided. Methods for detecting equatorial and axial conformation of a group other than hydrogen at the C2 position of a saccharide molecule are also provided. The compounds of the invention can be used as anti-cancer agents (e.g., against breast, ovarian, colon or renal cancers).Type: GrantFiled: September 8, 2000Date of Patent: March 11, 2003Assignee: The Regents of the University of CaliforniaInventors: Julie A. Leary, Sara P. Gaucher, Steven F. Pedersen
-
Patent number: 6518249Abstract: An oligosaccharide derivative, at higher homogeneity than fucose polysaccharide and rhamnose polysaccharide and with greater antiulcer effects, which is represented by the following general formula: Y—OCH(CH2NHR)2 wherein, Y represents an oligofucose or oligorhamnose at a polymerization number of 2 to 20, where the hydroxyl groups may or may not be partially modified in the form of sulfate ester, and R represents phenyl group, a higher alkylphenyl group, a higher alkyl group or —(CH2)n—NHX wherein n is an integer of 1 to 10 and X represents a higher alkanoyl group or an alkylamino group.Type: GrantFiled: February 18, 2000Date of Patent: February 11, 2003Assignee: Kabushiki Kaisha Yakult HonshaInventors: Masato Nagaoka, Hideyuki Shibata, Itsuko Kimura, Shusuke Hashimoto
-
Patent number: 6512100Abstract: The subject invention discloses materials and methods for the design, synthesis, and biochemical evaluation of chromogenic substrate compounds for sialidases of bacterial, viral, protozoa, and vertebrate (including humans) origin. In particular, this invention provides a novel class of effective compounds as chromogenic substrates of these sialidases which yield chromogenic products after reactions catalyzed by sialidase take place. Also provided are methods of making these substrate compounds, methods of diagnosis and prognosis of sialidase related diseases using these substrate compounds.Type: GrantFiled: August 30, 2000Date of Patent: January 28, 2003Assignees: Ibbex, Inc., UAB Research FoundationInventors: Stephen C Johnson, Ashraf Saeed, Ming Luo
-
Patent number: 6492342Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts and solvates thereof, wherein a, b, X, Y, Z, R1, R2, and R3 are as defined herein. The compounds of formula I are antibacterial and antiprotozoal agents useful for treating various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula I, to methods of treating bacterial and protozoal infections by administering the compounds of formula I, and to methods for preparing compounds of formula I.Type: GrantFiled: October 27, 2000Date of Patent: December 10, 2002Assignee: Pfizer Inc.Inventor: Takushi Kaneko
-
Patent number: 6486129Abstract: The present invention relates to compounds of formula (1), wherein R1 is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substitutents selected from (1-8C)alkyl or (1-8C)alkoxy; R2 and R3 are independently H or (1-8C)alkyl; R4 is (1-8C)alkyl or (3-8C)cycloalkyl; or R3 and R4 together with the nitrogen atom to which they are bonded are a nonaromatic (4-8)membered ring optionally containing another heteroatom, the ring optionally being substituted with (1-8C)alkyl or SO2-(1-8C)alkyl; Q is a spacer having a chain length of 10 to 70 atoms; and Z is a negatively charged oligosaccharide residue comprising two to six monosaccharide units, the charge being compensated by positively charged counterions; or a pharmaceutically acceptable salt thereof or a prodrug thereof.Type: GrantFiled: December 18, 2000Date of Patent: November 26, 2002Assignees: Akzo Nobel N.V., University LeidenInventors: Cornelia Maria Tromp, Johannes Egbertus Maria Basten, Constant Adriaan Anton van Boeckel, Rogier Christian Buijsman
-
Patent number: 6465625Abstract: Highly specific biocatalytic reactions have been used to create a population of taxol derivatives.Type: GrantFiled: June 19, 2000Date of Patent: October 15, 2002Assignee: Albany Molecular Research, Inc.Inventors: Jonathan S. Dordick, Douglas S. Clark, Peter C. Michels, Yuri L. Khmelnitsky
-
Patent number: 6444655Abstract: The present invention relates to simplified synthesis, new carbohydrate-based products and practical use of different carbohydrate-based products. Examples of these are (Gal&agr;1-3Gal), GlcNAc&bgr;1-3Gal, &agr;- or &bgr;-glycosides thereof, Gal&agr;1-3Gal- containing tri-, or higher oligosaccharides, &agr;- or &bgr;-glycosides thereof, GlcNAc&bgr;1-3Gal containing tri-, tetra-, or higher oligosaccharides, and derivatives and/or &agr;- or &bgr;-glycosides thereof, Gal&agr;1-3GalGlcNAc&bgr;1-3Gal, &agr;- or &bgr;-glycosides thereof, Gal&agr;1-3Gal&bgr;1-4GlcNAc&bgr;1-3Gal&bgr;1-4Glc, or other higher oligosaccharides containing the Gal&agr;1-3Gal-structure, &agr;- or &bgr;-glycosides thereof, modified carbohydrates, di-, tri-, oligo-, or polyfunctional products containing carbohydrate structures, and the use of the products for synthesis, affinity purification, diagnostic applications and therapy.Type: GrantFiled: June 19, 1998Date of Patent: September 3, 2002Assignee: Procur ABInventor: Kurt Nilsson
-
Patent number: 6420344Abstract: Glycosylated polyamines comprising of mono- or oligo-saccharides that are glycosidically linked to an aliphatic polyamine, and pharmaceutically acceptable salts, prodrugs and derivatives thereof are provided. An exemplary glycosylated polyamine has the following structure: Glycosylated polyamines, their pharmaceutically acceptable salts, prodrugs and derivatives are useful, for example, as anticancer compounds for the treatment of a variety of cancers. Methods for synthesis of glycosylated polyamines are disclosed. In addition, metal complexes of glycosylated polyamines, the preparation of such metal complexes, analytical methods using the metal complexes are provided. Methods for detecting equatorial and axial conformation of a group other than hydrogen at the C2 position of a saccharide molecule are also provided.Type: GrantFiled: March 14, 2000Date of Patent: July 16, 2002Assignee: The Regents of the University of CaliforniaInventors: Julie A. Leary, Sara P. Gaucher, Steven F. Pedersen
-
Patent number: 6417339Abstract: The invention relates to dendrimers comprising an initiator core with at least two functional groups and at least two saccharides, a process for preparing sch dendrimers as well as uses thereof.Type: GrantFiled: March 8, 1999Date of Patent: July 9, 2002Assignee: Deutsches Krebsforschungzentrum Stiftung des Offentlichen RechtsInventors: Manfred Wiessler, Markus Gschrey, Willi Von der Lieth, Walter Mier
-
Patent number: 6417167Abstract: The object of the present invention is to improve the solubility of sphingoglycolipids having low solubility in water. Disclosed is a lyophilized composition comprising the &agr;-glycosylceramide represented by the following formula (A) or a salt thereof, a polyoxysorbitan fatty acid ester and disaccharide or monosaccharide, and preferably additional deoxycholic acid or histidine, and a process for preparing it: wherein R1 represents H or OH; X denotes an integer in the range of 7-25; R2 represents any one of the substituents —CH2(CH2)YCH3, —CH(OH)(CH2)YCH3, —CH(OH)(CH2)YCH(CH3)2, —CH═CH(CH2)YCH3, or —CH(OH)(CH2)YCH(CH3)CH2CH3, wherein Y denotes an integer in the range of 5-17; either one of R3 or R4 represents H, and the other represents H, OH, NH2 or NHCOCH3; either one of R5 or R6 represents H, and the other represents OH; either one of R7 or R8 represents H, and the other represents OH; R9 represents H, CH3 or CH2OH.Type: GrantFiled: July 5, 2001Date of Patent: July 9, 2002Assignee: Kirin Beer Kabushiki KaishaInventors: Kazutoshi Maruyama, Hideaki Nomura, Akihiko Takeuchi
-
Publication number: 20020052326Abstract: SGLT2 inhibiting compounds are provided having the formula 1Type: ApplicationFiled: February 23, 2001Publication date: May 2, 2002Inventor: William N. Washburn
-
Patent number: 6348201Abstract: The present application discloses an external composition for skin comprising a component obtaind by washing a bacterium of the genus Sphingomonas with acetone and then extracting the resultant with alcohol or alcohol-water mixture; an external composition for skin comprising a component extracted from a white bacterium of the genus Sphingomonas; and an external composition for skin comprising a sphingoglycolipid represented by the following formula: where, R1 represents a sugar portion consisting of a single uronic acid or one to four hexoses selected from a group consisting of uronic acid, glucosamine, galactose and mannose; R2 represents an alkyl group which may have a cycloalkyl group, an alkenyl group or an alkynyl group; and R3 represents an alkyl group; these alkyl, alkenyl and alkynyl groups being straight or branched, and substituted or unsubstituted. These external compositions for skin exhibit excellent moisturizing and skin roughnes prevention effects.Type: GrantFiled: May 27, 1998Date of Patent: February 19, 2002Assignee: Kibun Food Chemifa Co., Ltd.Inventors: Katsumi Murata, Takashi Nozawa, Hisako Hara, Michiki Asai, Sachio Wakayama
-
Publication number: 20020010322Abstract: A subject of the invention is the compounds of formula (I): 1Type: ApplicationFiled: June 7, 2001Publication date: January 24, 2002Applicant: Aventis Pharma S.A.Inventors: Michel Klich, Patrick Laurin, Branislav Musicki, Laurent Schio
-
Patent number: 6340746Abstract: Disclosed are prodrugs as follows: (I) a prodrug of the formula where A is a sulfur or a selenium, and R is a mono- di- or oligo-saccharide; (II) a prodrug of the formula where A is sulfur or selenium, R′ is a sugar, or ═O, and the R″ groups are hydrogen, alkyl, alkoxy, carboxy; (III) a conjugate of an antioxidant vitamin and a thiolamine or selenolamine; (IV) a prodrug of the formula where A is sulfur or selenium, and R′ is a sugar, or an alkyl or aryl group, or ═O, and R‡ is an alkoxy, or an amine group; (V) a prodrug of the formula R is COOH or H, and R′ is a sugar or ═O.Type: GrantFiled: July 20, 2000Date of Patent: January 22, 2002Assignee: University of UtahInventors: Jeannette C. Roberts, Britta H. Wilmore, Pamela B. Cassidy, Pamela K. Dominick, Megan D. Short
-
Patent number: 6323339Abstract: One aspect of the present invention relates to differentially protected glycosyl phosphates. Another aspect of the present invention relates to the preparation of glycosyl phosphates from glycal precursors. In another aspect of the present invention, glycosyl phosphates are used as glycosyl donors in glycosylation reactions.Type: GrantFiled: October 6, 1999Date of Patent: November 27, 2001Assignee: Massachusetts Institute of TechnologyInventors: Peter H. Seeberger, Obadiah J. Plante
-
Patent number: 6313100Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1 and R2 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.Type: GrantFiled: January 7, 2000Date of Patent: November 6, 2001Assignee: Pfizer IncInventors: Katherine Elizabeth Brighty, Subramanian Sam Guhan, Martin Raymond Jefson, Robert Gerald Linde, III, Ellen Lester McCormick
-
Patent number: 6306915Abstract: The present invention provides a method of making an emulsified composition employing an emulsifier containing a sphingoglycolipid which has a structure represented by the following formula: wherein R1 is a saccharide moiety which consists of three to four hexoses selected from the group consisting of uronic acid, glucosamine, galactose, and mannose, or one uronic acid; R2 is an alkyl group, which may have a cycloalkyl group, an alkenyl group, or an alkynyl group; and R3 is an alkyl group. The alkyl group, the alkenyl group and the alkynyl group may have a normal chain or a branched chain, and may be substituted or unsubstituted. The emulsifier of the present invention has marked moisturizing effect, skin roughening preventing effect, and emulsifying effect.Type: GrantFiled: August 9, 1999Date of Patent: October 23, 2001Assignee: Kibun Food Chemifa Co., LtdInventor: Katsumi Murata
-
Patent number: 6303764Abstract: The present invention provides an improved method of preparing a 4,7-di-O-alkyl chromogenic ketoside of N-acetylneuraminic acid (Neu5Ac) for use in detecting influenza virus types A and B. The ketosides are substrates that are selectively cleaved by a neuraminidase on influenza virus, but not be neuraminidases found on other viruses or on bacteria. The synthesis is efficient and provides large quantities of the ketoside for commercial development. The synthesis includes a step of alkylating the 4- and 7-hydroxyl groups of a protected alkyl ester alkyl ketoside derivative of Neu5Ac by a process that comprises contacting the derivative with a composition comprising an alkyl halide to form a 4,7-di-O-alkyl protected alkyl ester alkyl ketoside derivative of Neu5Ac. The synthesis alternatively includes protecting the 8- and 9-hydroxyl groups of an alkyl ester alkyl ketoside derivative of Neu5Ac by forming an 8,9-epoxide protected alkyl ester alkyl ketoside derivative of Neu5Ac.Type: GrantFiled: September 24, 1999Date of Patent: October 16, 2001Assignees: Zymetx, Inc., Palladin Opportunity Fund, LLC, Halifex Fund, L.P.Inventors: Om Srivastava, Geeta Srivastava, Minghui Du, Ole Hindsgaul, David R. Bundle, Avraham Liav
-
Patent number: 6291434Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein X is R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10, are each, independently, hydrogen, acyl of 2-7 carbon atoms, perfluoroacyl of 2-10 carbon atoms, alkyl of 1-6 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, benzoyl, benzyl or —SO3M; M is hydrogen, lithium, sodium, potassium or ammonium; R11 is hydrogen, alkyl of 1-6 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, halogen, nitrile, nitro, or alkoxy of 1-6 carbon atoms; R12 is hydrogen, nitro, amino, acylamino of 2-7 carbon atoms, perfluoroacylamino of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, perfluoroalkylamino of 1-6 carbon atoms, dialklylamino where each alkyl chain is independently 1-6 carbon atoms, perfluorodialklylamino where each alkyl chain is independently 1-6 carbon atoms alkylsulfonylamino of 1-6 carbon atoms, perfluoroalkylsulfonylamino of 1-6 carbon atoms, arylsulfonylamino of 6-10Type: GrantFiled: November 22, 1999Date of Patent: September 18, 2001Assignee: American Home Products Corp.Inventor: Paul J. Dollings
-
Patent number: 6281342Abstract: Disclosed are novel pradimicin compounds which possess antifungal activity and, preferably, improved water solubility. The compounds of the invention are prepared by modifying the 4′-amino or 4′-alkylamino moieties of known pradimicin compounds.Type: GrantFiled: May 12, 1994Date of Patent: August 28, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Hajime Kamachi, Minoru Hirano, Shinji Masuyoshi
-
Patent number: 6265555Abstract: A composition with a high ganglioside content is manufactured by a method characterized in that milk or milk-derived material containing ganglioside is dispersed in an ethanol solution so that the concentration of ethanol becomes 60˜95%; after removing the precipitate which is generated by heating the solution to a temperature higher than 50° C., the obtained supernatant is cooled to a temperature lower than 0° C; and the obtained precipitate is recovered. The obtained composition with a high ganglioside content is used advantageously as a material for foods and drinks, medicines, chemical products, etc.Type: GrantFiled: February 9, 2000Date of Patent: July 24, 2001Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Minoru Morita, Makihiro Sugawara, Masayuki Eto, Susumu Miura, Masanori Kotani
-
Patent number: 6245745Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X1 and X2 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1, methods of treating bacterial and protozoal infections by administering the compounds of formula 1, and methods of preparing certain compounds of formula 1.Type: GrantFiled: December 2, 1999Date of Patent: June 12, 2001Assignee: Pfizer IncInventor: Mathew Merrill Hayward
-
Patent number: 6245902Abstract: The invention provides versatile sialic acid C-glycoside precursors that are useful for preparing C-glycoside analogs of Gangliosides, peptides, and proteins, as well as synthetic intermediates useful for the preparation of the precursors, and synthetic methods useful for preparing the precursors and the intermediates. The invention also provides gangliosides, peptides, and proteins that comprise sialic acid C-glycoside components, as well as synthetic methods useful for the preparation of such compounds.Type: GrantFiled: August 9, 1999Date of Patent: June 12, 2001Assignee: University of Iowa Research FoundationInventors: Robert J. Linhardt, Helene G. Bazin, Yuguo Du, Tulay Polat
-
Patent number: 6218367Abstract: The present invention provides novel, water soluble, carbohydrate derivatives of paclitaxel, methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such compounds. The compounds of the invention are modified at the 2′ or 7 position of paclitaxel and have the general formula [paclitaxel]-[link]1−2-[sugar]. These compounds show improved biological activity toward many cancer cell lines as compared to paclitaxel. Additionally, the conjugates are made from natural non-toxic materials which, when released, will be adsorbed as part of the body components.Type: GrantFiled: September 14, 1999Date of Patent: April 17, 2001Assignee: Organomed CorporationInventor: James N Jacob
-
Patent number: 6204002Abstract: The invention provides a compound represented by the following formula (I) wherein m is an integer of 2-15; n is an integer of 0-12; R represents a sugar chain or a derivative thereof; R′ represents a general formula (II) (wherein p is an integer of 0-4, q is an integer of 0-5; r is an integer of 2-5; R12 and R13 are the same or different and each represents a hydrogen atom, a lower alkyl group, an aliphatic acyl group, a nitro group or a nitrile group), R1 represents a hydrogen atom or a protective group of carboxylic acid, R2, R4 and R5 are the same or different and each represents a hydrogen atom, an aliphatic or aromatic acyl group; R3 represents an acetyl group, a glycolyl group or a trifluoroacetyl group; useful as reagent for detecting influenza virus A.Type: GrantFiled: December 23, 1998Date of Patent: March 20, 2001Assignee: Daikin Industries, Ltd.Inventors: Takao Iida, Yutaka Ohira
-
Patent number: 6184366Abstract: Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein.Type: GrantFiled: April 16, 1999Date of Patent: February 6, 2001Assignee: Eisai Co., LTDInventors: William J. Christ, Daniel P. Rossignol